Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: The cost-effectiveness of a decision rule for abdominal complaints in primary care (CEDAR) study

Clinical Chemistry

Volumn 58, Issue 6, 2012, Pages 989-998

  Kok, Liselotte ^a   Elias, Sjoerd G ^a   Witteman, Ben J M ^b   Goedhard, Jelle G ^c   Muris, Jean W M ^d   Moons, Karel G M ^a   De Wit, Niek J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; COLON ADENOCARCINOMA; COLON ADENOMA; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEFECATION DISORDER; DEVICES; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENTERITIS; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH CARE COST; HISTOLOGY; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RECTUM HEMORRHAGE; SIGMOIDOSCOPY;

ADENOCARCINOMA; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIVERTICULITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GENERAL PRACTICE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; INTESTINAL NEOPLASMS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; OCCULT BLOOD; POINT-OF-CARE SYSTEMS; PRIMARY HEALTH CARE; PROCTITIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

NUCLEOPOLYHEDROVIRUS;

EID: 84861696546     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.177980     Document Type: Article

References (33)

1. Muris JW, Starmans R, Fijten GH, Knottnerus JA. One-year prognosis of abdominal complaints in general practice: a prospective study of patients in whom no organic cause is found. Br J Gen Pract 1996;46:715-9. (Pubitemid 26417800)
2. Vandvik PO, Kristensen P, Aabakken L, Farup PG. Abdominal complaints in general practice. Scand J Prim Health Care 2004;22:157- 62.
3. Janssen HA, Borghouts JA, Muris JW, Metsemakers JF, Koes BW, Knottnerus JA. Health status and management of chronic non-specific abdominal complaints in general practice. Br J Gen Pract 2000;50:375-9. (Pubitemid 30245616)
4. Balaguer F, Llach J, Castells A, Bordas JM, Pellisé M, Rodriguez-Moranta A, et al. The European panel on the appropriateness of gastrointestinal endoscopy guidelines colonoscopy in an openaccess endoscopy unit: a prospective study. Aliment Pharmacol Ther 2005;21:609-13. (Pubitemid 40381512)
5. Gonvers JJ, Harris JK, Wietlisbach V, Burnand B, Vader JP, Froehlich FA. European view of diagnostic yield and appropriateness of colonoscopy. Hepatogastroenterology 2007;54:729-35. (Pubitemid 46903711)
6. Morini S, Hassan C, Meucci G, Toldi A, Zullo A, Minoli G. Diagnostic yield of open access colonoscopy according to appropriateness. Gastrointest Endosc 2001;54:175-9.
7. Verma S, Giaffer MH. Open-access versus hospital-initiated flexible sigmoidoscopy: a comparative audit of efficacy. Eur J Gastroenterol Hepatol 2001;13:655-8. (Pubitemid 32547863)
8. Farup PG, Vandvik PO, Aabakken L. How useful are the Rome II criteria for identification of gastrointestinal disorders in general practice? Scand J Gastroenterol 2005;40:1284-9. (Pubitemid 41658726)
9. Fijten GH, Muris JW, Starmans R, Knottnerus JA, Blijham GH, Krebber TF. The incidence and outcome of rectal bleeding in general practice. Fam Pract 1993;10:283-7. (Pubitemid 23322334)
10. Starmans R, Muris JW, Fijten GH, Schouten HJ, Pop P, Knottnerus JA. The diagnostic value of scoring models for organic and non-organic gastrointestinal disease, including the irritable-bowel syndrome. Med Decis Making 1994;14:208 -16.
11. Boukes FS, van der Horst HE, Assendelft WJ. Summary of the Dutch College of General Practitioners' 'Irritable bowel syndrome' standard. Ned Tijdschr Geneeskd 2002;146:799-802. [Dutch] (Pubitemid 34453386)
12. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770 -98.
13. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60. (Pubitemid 34827189)
14. Kost GJ. Preventing medical errors in point-ofcare testing. Security, validation, performance, safeguards, and connectivity. Arch Pathol Lab Med 2001;125:1307-15.
15. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
16. Jellema P, van Tulder MW, van der Horst HE, Florie J, Mulder CJ, van der Windt DA. Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care. Colorectal Dis 2011;13:239-54.
17. Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, de Vet HC. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and metaanalysis. BMJ 2010;340:c1269.
18. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010;24:479-92.
19. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue(R) rapid test for faecal calprotectin. Ann Clin Biochem 2012;49:55-8.
20. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-12.
21. van Gool T, Weijts R, Lommerse E, Mank TG. Triple faeces test: an effective tool for detection of intestinal parasites in routine clinical practice. Eur J Clin Microbiol Infect Dis 2003;22:284-90. (Pubitemid 36760450)
22. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002;51 Suppl 5:V6-9. (Pubitemid 35222897)
23. Nagengast FM, Kaandorp CJ. Revised CBO guideline 'Follow-up after polypectomy.' Ned Tijdschr Geneeskd 2001;145:2022-5. [Dutch] (Pubitemid 32979472)
24. Sobin LH. The histopathology of bleeding from polyps and carcinomas of the large intestine. Cancer 1985;55:577-81. (Pubitemid 15156026)
25. Crowley ML, Freeman LD, Mottet MD, Strong RM, Sweeney BF, Brower FA, et al. Sensitivity of guaiacimpregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol 1983;5:127-30. (Pubitemid 13110386)
26. Foutch PG, Manne RK, Sanowski RA, Gaines JA. Risk factors for blood loss from adenomatous polyps of the large bowel: a colonoscopic evaluation with histopathological correlation. J Clin Gastroenterol 1988;10:50-6. (Pubitemid 18062522)
27. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6. (Pubitemid 36078546)
28. Bühlmann Laboratories AG. Calprotectin ELISA EK-CAL, instructions for use. Schonenbüch/Basel, Switzerland, 2008.
29. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.
30. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
31. Joshi S, Lewis SJ, Creanor S, Ayling RM. Agerelated faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63.
32. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:279-84. (Pubitemid 38222561)
33. Marshall T, Lancashire R, Sharp D, Peters TJ, Cheng KK, Hamilton W. The diagnostic performance of scoring systems to identify symptomatic colorectal cancer compared to current referral guidance. Gut 2011;60:1242-8.